Sensorineural Hearing Loss clinical trials at UCLA

1 research study open to eligible people

Showing trials for

  • DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations

    open to eligible people ages up to 17 years

    Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene. The purpose of this study is to: - Learn about the safety of DB-OTO - Determine how well DB-OTO is tolerated (does not cause ongoing discomfort) - Evaluate the efficacy of DB-OTO (how well DB-OTO works)

    Los Angeles 5368361, California 5332921 and other locations

Our lead scientists for Sensorineural Hearing Loss research studies include .

Last updated: